Bio & Pharma
S.Korea's Prestige Biologics attracts $59 mn overseas investment
The company plans to take more CDMO orders by securing cash flow and strengthening financial soundness
By Mar 15, 2023 (Gmt+09:00)
1
Min read
Most Read
Hankook Tire buys $1 bn Hanon Systems stake from Hahn & Co.
S.Korea's LS Materials set to boost earnings ahead of IPO process
NPS to hike risky asset purchases under simplified allocation system
Aman, Rosewood, Banyan, IHG rush to open luxury hotels in Seoul
Osstem to buy Brazil’s No. 3 dental implant maker Implacil
Prestige Biologics Co., a South Korean biopharmaceutical contract development and manufacturing organization (CDMO) company, announced on Tuesday that it had raised 45.5 billion won ($59.4 million) in investment from Octava Fund Limited, a Singapore-based firm.
Octava Fund is the second-largest shareholder of Prestige Biopharma, the largest shareholder and an affiliate of Prestige Biologics. The investment was made through the issuing of convertible bonds.
Prestige Biologics stated that the latest investment will provide the company with cash flow and enhance its financial stability, allowing it to pursue CDMO orders more aggressively.
According to CEO Hyun Deok-hoon, the company aims to become a global CDMO by fully utilizing a 154,000-liter-capacity plant and securing orders from large clients, while also expanding funds to proactively respond to domestic and international economic challenges.
Write to Ji-Hyun Lee at bluesky@hankyung.com
More to Read
-
Bio & PharmaPrestige Bio's Herceptin biosimilar proves equivalence in clinical trials
Feb 08, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaPrestige Biopharma submits clinical trial plan in Australia
Feb 03, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaPrestige Biopharma attains patent for solid cancer treatment antibody
Jan 12, 2023 (Gmt+09:00)
1 Min read
Comment 0
LOG IN